The worldwide supply of nuclear medicine relies on the production of radioactive materials from a mere six government-run nuclear research reactors. Each year, the reliability of the supply chain responsible for life-saving radiopharmaceuticals becomes increasingly brittle as these facilities age or are slated to be shut down. Founder/CEO Thomas Eiden explains why he left what most would consider a dream job to create Atomic Alchemy Inc., and how his company plans to end this looming crisis.